Genentech Halts Avastin Trial Enrollment Due To GI Perforations
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.